Menu
← Oncology Approval Tracker
FDA DECISION ·
Vivimusta
bendamustine hydrochloride · Slayback Pharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Bendamustine injection for adults with CLL or indolent B-cell NHL that progressed during or within six months after rituximab or a rituximab-containing regimen.
LAMPGEN ANALYSIS
Why it matters
The branded injection approval adds a product-specific bendamustine option in established indications.
What research teams should watch
Use Vivimusta’s own preparation and infusion instructions when adding the presentation to a formulary.
PRIMARY RECORDS